Literature DB >> 31544169

Prolonged Partial Response to Bevacizumab and Valproic Acid in a Patient With Glioblastoma.

Elena Fountzilas1, Gary Palmer2, David Vining1, Apostolia-Maria Tsimberidou1.   

Abstract

Entities:  

Year:  2018        PMID： 31544169      PMCID： PMC6753784          DOI： 10.1200/PO.18.00282

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  38 in total

1.  Tumor vasculature is regulated by FGF/FGFR signaling-mediated angiogenesis and bone marrow-derived cell recruitment: this mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs.

Authors:  Pierre Fons; Geneviève Gueguen-Dorbes; Jean-Pascal Herault; Fabien Geronimi; Joël Tuyaret; Dol Frédérique; Paul Schaeffer; Cécile Volle-Challier; Jean-Marc Herbert; Françoise Bono
Journal:  J Cell Physiol       Date:  2015-01       Impact factor: 6.384

Review 2.  Fibroblast growth factors and their receptors in cancer.

Authors:  Jørgen Wesche; Kaisa Haglund; Ellen Margrethe Haugsten
Journal:  Biochem J       Date:  2011-07-15       Impact factor: 3.857

3.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Christine E Brown; Darya Alizadeh; Renate Starr; Lihong Weng; Jamie R Wagner; Araceli Naranjo; Julie R Ostberg; M Suzette Blanchard; Julie Kilpatrick; Jennifer Simpson; Anita Kurien; Saul J Priceman; Xiuli Wang; Todd L Harshbarger; Massimo D'Apuzzo; Julie A Ressler; Michael C Jensen; Michael E Barish; Mike Chen; Jana Portnow; Stephen J Forman; Behnam Badie
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

4.  Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.

Authors:  M S Kim; H J Kwon; Y M Lee; J H Baek; J E Jang; S W Lee; E J Moon; H S Kim; S K Lee; H Y Chung; C W Kim; K W Kim
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

5.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

Review 7.  Gene amplification in human gliomas.

Authors:  V P Collins
Journal:  Glia       Date:  1995-11       Impact factor: 7.452

8.  Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2.

Authors:  G Reifenberger; J Reifenberger; K Ichimura; P S Meltzer; V P Collins
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

9.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.

Authors:  Anna Luisa Di Stefano; Alessandra Fucci; Veronique Frattini; Marianne Labussiere; Karima Mokhtari; Pietro Zoppoli; Yannick Marie; Aurelie Bruno; Blandine Boisselier; Marine Giry; Julien Savatovsky; Mehdi Touat; Hayat Belaid; Aurelie Kamoun; Ahmed Idbaih; Caroline Houillier; Feng R Luo; Jean-Charles Soria; Josep Tabernero; Marica Eoli; Rosina Paterra; Stephen Yip; Kevin Petrecca; Jennifer A Chan; Gaetano Finocchiaro; Anna Lasorella; Marc Sanson; Antonio Iavarone
Journal:  Clin Cancer Res       Date:  2015-01-21       Impact factor: 13.801
View more
  2 in total

1.  Synthetic mRNA-based gene therapy for glioblastoma: TRAIL-mRNA synergistically enhances PTEN-mRNA-based therapy.

Authors:  Xiangjun Tang; Hao Peng; Pengfei Xu; Li Zhang; Rui Fu; Hanjun Tu; Xingrong Guo; Kuanming Huang; Junti Lu; Hu Chen; Zhiqiang Dong; Longjun Dai; Jie Luo; Qianxue Chen
Journal:  Mol Ther Oncolytics       Date:  2022-02-02       Impact factor: 7.200

2.  Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.

Authors:  Yu-Jen Kuo; Yao-Hsu Yang; I-Yun Lee; Pau-Chung Chen; Jen-Tsung Yang; Ting-Chung Wang; Martin Hsiu-Chu Lin; Wei-Hsun Yang; Chun-Yu Cheng; Kuo-Tai Chen; Wei-Chao Huang; Ming-Hsueh Lee
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.